Navigation Links
Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Date:2/6/2013

ANAHEIM, Calif., Feb. 6, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced that it will release fourth quarter and full year 2012 financial results on Tuesday, February 26, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, February 26, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter and full year, as well as current corporate developments.

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website, http://ir.questcor.com/.
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 95427085.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications:  the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, the treatment of infantile spasms in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit www.questcor.com.

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
2. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
3. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
4. Questcor to Conduct Conference Call to Discuss Reimbursement Process
5. Questcor Comments on Insurance Policy Bulletin
6. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
7. Questcor Pharmaceuticals to Present at Investor Conferences in September
8. Questcor Reports Second Quarter Financial Results
9. Questcor to Report Second Quarter Results on July 24, 2012
10. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
11. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2020)... , ... January 03, 2020 , ... In Partnership with ... dental services for low-income, underinsured individuals at its Burleson, TX office on February 8th. ... fillings , cleanings and extractions . For more information, please ...
(Date:1/3/2020)... ... January 03, 2020 , ... Complia Health announced today the ... will offer enterprise solutions for home, residential and community care in Canada, Australia ... and will move forward under the AlayaCare brand. , Procura has delivered home, ...
(Date:1/2/2020)... ... January 02, 2020 , ... ... presentations that address all levels of psychiatric-mental health nursing administration, education, practice, ... presentations to 1800+ registered and advanced practice nurses. Nurses from varied backgrounds ...
Breaking Medicine Technology:
(Date:1/10/2020)... ... January 10, 2020 , ... WellHaven Pet Health, a family of companion animal ... community coming in February 2020, LEAD WELL with WOMEN. The community will be showcased ... vision of LEAD WELL with WOMEN is to empower women, engage all, connect, and ...
(Date:1/10/2020)... OAK BROOK, Ill. (PRWEB) , ... January 10, ... ... Nursing (BCEN) today announced that its Certified Pediatric Emergency Nurse (CPEN) ... Specialty Nursing Certification (ABSNC). , The CPEN is a national board certification ...
(Date:1/8/2020)... ... January 08, 2020 , ... Quality Health Care Concierge ... holistic care approach and to maintain a comfortable and preferred lifestyle with their Companion ... passion for holistic care and has been a leader in the healthcare field for ...
(Date:1/7/2020)... N.C. (PRWEB) , ... January 07, 2020 , ... ... of Ian Petersen, MBA, as Executive Director of Foothills at Red Oak Recovery ... as a mentor at one of the nation's leading residential treatment centers for ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... impairment, has announced the Best Memory Care Facilities in Lakeland, Florida. The guide ... and amenities. , According to the Alzheimer’s Association , 5.6 million ...
Breaking Medicine News(10 mins):